vault backup: 2025-12-08 07:25:57
This commit is contained in:
281
content/Biokemi/Metabolism/Aminosyrametabolism/Slides.md
Normal file
281
content/Biokemi/Metabolism/Aminosyrametabolism/Slides.md
Normal file
@@ -0,0 +1,281 @@
|
||||
---
|
||||
föreläsare: Martin Lidell
|
||||
tags:
|
||||
- biokemi
|
||||
- aminosyrametabolism
|
||||
- slides
|
||||
date: 2025-12-08
|
||||
---
|
||||
# LPG001
|
||||
Martin Lidell
|
||||
Amino acid metabolism
|
||||
|
||||
## Lecture outline
|
||||
Amino acids – a short introduction
|
||||
How do we get access to amino acids?
|
||||
Biosynthesis of non-essential amino acids
|
||||
The origin of the a-amino group and the carbon skeleton
|
||||
Degradation of amino acids
|
||||
What happens with the amino group and the carbon skeleton?
|
||||
The urea cycle
|
||||
Transport of nitrogen to the liver (alanine/glutamine)
|
||||
Examples of some defects in amino acid metabolism
|
||||
|
||||
## Amino acids
|
||||
Definition:
|
||||
An amino acid is a simple organic
|
||||
compound containing both a carboxyl
|
||||
and an amino group
|
||||
More than 500 different amino acids
|
||||
have been described in nature
|
||||
Twenty a-amino acids (21 if including
|
||||
selenocysteine) are commonly found
|
||||
in mammalian proteins. These
|
||||
proteinogenic amino acids are the
|
||||
only amino acids that are coded for
|
||||
by DNA
|
||||
|
||||
## Amino acids – examples of some important non-proteinogenic amino acids
|
||||
GABA (g-amino acid)
|
||||
g-aminobutyric acid (GABA)
|
||||
an inhibitory neurotransmitter
|
||||
Ornithine and Citrulline
|
||||
intermediates in the urea cycle
|
||||
Ornithine (a-amino acid)
|
||||
Citrulline (a-amino acid)
|
||||
|
||||
## Why are amino acids essential biomolecules? – some examples
|
||||
Building blocks in proteins
|
||||
Precursors of important biomolecules
|
||||
(neurotransmitters, hormones, etc. etc.)
|
||||
Dopamine Epinephrine
|
||||
Source of energy
|
||||
Acts as neurotransmitters (e.g. Glu and Gly)
|
||||
Involved in acid-base homeostasis (Gln)
|
||||
Transport ammonia in a nontoxic form (Gln and Ala)
|
||||
|
||||
## Overview of amino acid metabolism
|
||||
Endogenous proteins
|
||||
De novo synthesis of non-essential amino acids
|
||||
Dietary proteins
|
||||
Synthesis of other important biomolecules
|
||||
Degradation
|
||||
Amino group → Urea
|
||||
Carbon skeleton → Ketone bodies, Glucose/glycogen, Energy, CO2 + H2O, Fatty acids
|
||||
Refilling reactions
|
||||
Amino acids
|
||||
Urea cycle
|
||||
|
||||
## Digestion of dietary proteins in the gastrointestinal tract
|
||||
|
||||
## Amino acids, di- and tripeptides are absorbed by the enterocytes and released as amino acids into the blood
|
||||
The absorbed di- and tripeptides are digested by peptidases into free amino acids that are released into the blood
|
||||
|
||||
## Intracellular degradation of endogenous proteins – released amino acids can be reused
|
||||
Proteasomal degradation
|
||||
|
||||
## Biosynthesis of amino acids – the a-amino group and the carbon skeletons
|
||||
|
||||
## Biosynthesis of amino acids – the a-amino group
|
||||
The a-amino group is most often derived from glutamate
|
||||
|
||||
## Biosynthesis of amino acids – the carbon skeletons
|
||||
|
||||
## Most microorganisms can synthesize all of the common proteinogenic amino acids
|
||||
|
||||
## Biosynthesis of amino acids in humans – essential and nonessential amino acids
|
||||
Nonessential:
|
||||
Alanine, Arginine, Asparagine, Aspartate, Cysteine, Glutamate, Glutamine, Glycine, Proline, Serine, Tyrosine
|
||||
Essential:
|
||||
Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine
|
||||
|
||||
Humans cannot make the essential amino acids; they must be supplied in the diet
|
||||
Some nonessential amino acids become essential under certain circumstances (“conditionally essential”)
|
||||
e.g. arginine for fetus/neonate; tyrosine in PKU
|
||||
|
||||
## Biosynthesis of nonessential amino acids in humans
|
||||
The carbon skeletons are derived from five precursors:
|
||||
• 3-Phosphoglycerate
|
||||
• Pyruvate
|
||||
• a-Ketoglutarate
|
||||
• Oxaloacetate
|
||||
• Phenylalanine
|
||||
|
||||
## Formation of glutamate from a-ketoglutarate
|
||||
Glutamate is primarily formed in transamination reactions catalyzed by different aminotransferases
|
||||
|
||||
## Aminotransferases / Transaminases
|
||||
Enzymes transferring amino groups from a-amino acids to a-keto acids
|
||||
a–amino acid-R1 + a–keto acid-R2 → a–keto acid-R1 + a–amino acid-R2
|
||||
a-Ketoglutarate/Glutamate is the most common amino group acceptor/donor pair.
|
||||
The reactions are reversible.
|
||||
Essential for both synthesis and degradation of amino acids.
|
||||
|
||||
## ALT and AST – two important aminotransferases
|
||||
Amino acids: Alanine, Aspartate, Glutamate
|
||||
a-Keto acids: Pyruvate, Oxaloacetate, a-ketoglutarate
|
||||
|
||||
## Aminotransferases as indicators of tissue damage
|
||||
• Intracellular enzymes
|
||||
• Elevated plasma levels indicate cell damage
|
||||
• ALT mostly in liver
|
||||
• AST in liver, heart, skeletal muscle, kidney
|
||||
|
||||
## A second route of synthesis of glutamate from a-ketoglutarate
|
||||
Glutamate dehydrogenase (mitochondrial, liver-specific)
|
||||
|
||||
## Arginine and proline – synthesized from glutamate
|
||||
Arginine → part of urea cycle
|
||||
|
||||
## Glutamine and asparagine – formed by amidation
|
||||
Enzymes: glutamine synthetase, asparagine synthetase
|
||||
|
||||
## Tyrosine – synthesized from phenylalanine
|
||||
Reaction:
|
||||
Phenylalanine + O2 + NADPH + H+ → Tyrosine + NADP+ + H2O
|
||||
|
||||
## Phenylketonuria (PKU)
|
||||
Accumulation of phenylalanine, phenylpyruvate, phenyllactate, phenylacetate
|
||||
Deficiency of tyrosine and metabolites
|
||||
Autosomal recessive (PAH gene)
|
||||
Hundreds of mutations
|
||||
Insufficient phenylalanine hydroxylase activity
|
||||
|
||||
## PKU symptoms
|
||||
Intellectual disability, delayed development, seizures, musty odor, fair skin/blue eyes
|
||||
Treatment: dietary restriction, amino acid mix w/o Phe, tyrosine becomes essential, sapropterin may help
|
||||
|
||||
## “PKU-provet” – newborn screening since 1965
|
||||
Blood sample after 48 hours
|
||||
Purpose: detect treatable congenital diseases early
|
||||
|
||||
## Diseases included today (25 total)
|
||||
Endocrine diseases (2)
|
||||
Fatty acid metabolism defects (3)
|
||||
Carnitine system defects (4)
|
||||
Organic acidurias (6)
|
||||
Urea cycle defects (3)
|
||||
Amino acid metabolism defects (4)
|
||||
Other metabolic diseases (2)
|
||||
SCID
|
||||
|
||||
## Summary of part 1
|
||||
(Amino acids important, sources, essential vs nonessential, aminotransferases, PKU)
|
||||
|
||||
## Excess amino acids cannot be stored
|
||||
Amino acids not needed → degraded to intermediates that enter central metabolism
|
||||
|
||||
## How are amino acids degraded?
|
||||
• Remove a-amino group
|
||||
• Carbon skeleton becomes pyruvate, TCA intermediates, acetyl-CoA, acetoacetyl-CoA
|
||||
Occurs primarily in liver; skeletal muscle degrades branched-chain amino acids
|
||||
|
||||
## Challenge: ammonia toxicity
|
||||
Solution: liver → urea cycle
|
||||
Other tissues → transport as glutamine/alanine
|
||||
|
||||
## Glutamate as intermediate toward urea
|
||||
|
||||
## a-amino groups transfer to a-ketoglutarate → glutamate (ALT/AST)
|
||||
|
||||
## Oxidative deamination of glutamate
|
||||
Glutamate dehydrogenase (liver mitochondrial matrix)
|
||||
|
||||
## Serine and threonine can be directly deaminated (dehydratases)
|
||||
|
||||
## Side-chain nitrogen of glutamine and asparagine – release ammonia and form glutamate
|
||||
|
||||
## Ammonia is toxic to CNS
|
||||
Urea cycle detoxifies ammonia
|
||||
Only active in liver
|
||||
|
||||
## Urea cycle
|
||||
Carbamoyl phosphate synthetase I
|
||||
Ornithine transcarbamoylase
|
||||
Argininosuccinate synthetase
|
||||
Argininosuccinate lyase
|
||||
Arginase
|
||||
Urea contains 2 amino groups: one from NH4+, one from aspartate.
|
||||
Carbon from HCO3–
|
||||
|
||||
## Why is ammonia toxic? (theory)
|
||||
Glutamine synthetase in astrocytes → glutamine accumulation → osmotic swelling → edema
|
||||
|
||||
## Regulation of urea cycle
|
||||
N-acetylglutamate activates CPS I
|
||||
High glutamate + arginine → more N-acetylglutamate
|
||||
|
||||
## Defects in urea cycle – example: argininosuccinate lyase deficiency
|
||||
Autosomal recessive
|
||||
Symptoms: hyperammonemia, irregular breathing, hypotonia, vomiting, alkalosis, brain swelling, seizures
|
||||
Treatment: glucose infusion, drugs promoting nitrogen excretion, dialysis, low-protein diet, liver transplant
|
||||
|
||||
## Drug treatment: arginine and phenylbutyrate
|
||||
|
||||
## Nitrogen transport from extrahepatic tissues
|
||||
Extrahepatic tissues lack urea cycle
|
||||
Transport forms: glutamine and alanine
|
||||
Muscle uses BCAA
|
||||
|
||||
## Glutamine and alanine – nitrogen carriers
|
||||
|
||||
## Glucose-alanine cycle
|
||||
|
||||
## Where do carbon skeletons end up?
|
||||
|
||||
## Seven end-products of amino acid carbon skeleton degradation
|
||||
|
||||
## Citric acid cycle – source of building blocks
|
||||
Cycle must be refilled (anaplerosis)
|
||||
|
||||
## Anaplerotic reactions
|
||||
Pyruvate, amino acid skeletons refill TCA
|
||||
|
||||
## Glucogenic vs ketogenic amino acids
|
||||
Glucogenic → pyruvate or TCA intermediates → glucose
|
||||
Ketogenic → acetyl-CoA or acetoacetyl-CoA → ketone bodies
|
||||
13 glucogenic
|
||||
5 mixed (Phe, Iso, Thr, Trp, Tyr)
|
||||
2 ketogenic only (Lys, Leu)
|
||||
|
||||
## Oxaloacetate as entry point for Asp/Asn
|
||||
|
||||
## a-Ketoglutarate as entry point for several amino acids
|
||||
Glutamate → a-ketoglutarate (via GDH)
|
||||
|
||||
## Degradation pathways generating acetyl-CoA
|
||||
|
||||
## Degradation of phenylalanine and tyrosine
|
||||
|
||||
## Degradation of branched-chain amino acids
|
||||
Occurs mainly in skeletal muscle
|
||||
|
||||
## Maple syrup urine disease (MSUD)
|
||||
Autosomal recessive
|
||||
Defect in branched-chain a-keto acid dehydrogenase complex
|
||||
Accumulation of Leu, Iso, Val and their keto acids
|
||||
Symptoms: poor feeding, vomiting, low energy, abnormal movements, delayed development; severe cases seizures/coma
|
||||
Treatment: protein-restricted diet lacking Leu/Iso/Val; controlled supplementation
|
||||
|
||||
## Summary of part 2
|
||||
• Amino acid degradation → ammonia → toxic
|
||||
• Glutamate central
|
||||
• Liver → only site of urea production
|
||||
• Extrahepatic tissues use glutamine/alanine
|
||||
• Carbon skeletons used for refilling, glucose, ketone bodies, fatty acids, energy
|
||||
|
||||
## Some important enzymes
|
||||
ALT
|
||||
AST
|
||||
Glutamate dehydrogenase
|
||||
Glutamine synthetase
|
||||
Glutaminase
|
||||
Phenylalanine hydroxylase
|
||||
Carbamoyl phosphate synthetase I
|
||||
|
||||
## Läsanvisningar
|
||||
Biochemistry (Berg et al.)
|
||||
Chapter 23: 701–703, 708–731
|
||||
Chapter 25: 766–790
|
||||
Instuderingsfrågor på Canvas
|
||||
Amino acid metabolism
|
||||
Reference in New Issue
Block a user